The outside of a perscan machine with the tube in the center

REALLY dreading these #petscan results. Last one sent me on a wild goose chase with more MRI, CT, U/S, with no real answers and elevating #signatera results. my lower back and hips hurt like hell and I think it's more cancer😔 I hate cancer. #metastaticbreastcancer

🎗️4 февруари - Световен ден за борба с рака🎗️

Борбата с рака не се ограничава само до един ден всяка година! #Signatera е авангарден #генетичен #тест и анализира свободно циркулираща туморна ДНК (ctDNA) в кръвта, за да осигури персонализирано и надеждно проследяване👇
nmgenomix.com/%D0%B4%D0%BE...

Natera $NTRA aims to boost #Signatera sensitivity and expand into the hematological oncology market with the $274M acquisition of Foresight Diagnostics

Natera’s technology will be featured across multiple presentations at #ESMO2025. See the full schedule below and stop by booth #1016 to learn more. #Natera #MRD #Signatera
@myesmo.bsky.social

Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon

"Signatera gives me the power to go on with my life instead of constantly wondering ‘what-if.’"

Two days after a visit to the emergency room, Holly underwent surgery and received a rare ovarian cancer diagnosis.

www.natera.com/resource-lib...

#OvarianCancerAwareness #Signatera #MRDtesting #Natera

Adanma Ayanambakkam, MD, genitourinary oncologist at Stephenson Cancer Center shares recent data on the prognostic value of ctDNA-based MRD detection in patients with upper tract urothelial cancer.
#MRDTesting #Natera #Signatera

Watch the video: www.natera.com/resource-lib...

Natera Announces Medicare Coverage for Signatera™ Genome Broad coverage, inclusive of all previously covered Signatera indications AUSTIN, Texas–(BUSINESS WIRE)– Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today ann...

We’re pleased to announce that our genome-based Signatera MRD assay is now covered by Medicare.

This is an exciting milestone as we continue advancing precision oncology and expanding access to innovative technology. ow.ly/KQcR50W4nji

#Natera #Signatera #MRD #PrecisionMedicine #Oncology

Thank you for visiting our booth at #ASCO25 & to our team for their work in making the event a success!
Congrats to Dr. Marla Lipsyc-Sharf, Dr. Julia Foldi & Dr. Mridula George & all of our presenters showcasing the clinical impact of #Signatera. ow.ly/rhxV50W1Osv @ascocancer.bsky.social

Learn more about Signatera and the foundational technology that is transforming care for patients with cancer. Hear from #Natera CEO Steve Chapman on how Signatera can detect molecular residual disease and help determine whether therapy is working. youtu.be/fLkJlNzL3hU

#CancerCare #Signatera

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100% Leiomyosarcoma, the most common subtype in the cohort, ...

Largest #sarcoma study to date with ctDNA analysis demonstrates excellent performance for #Signatera. The Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100%.

www.natera.com/company/news...
#MRD #Natera

Make more informed treatment decisions 💙 Learn how #Natera supports people on their healthcare journeys. #Oncology #CancerAwareness #Signatera

Anyone who is getting #Signatera #ctDNA #Natera liquid biopsy approved for #StageIV #ColonCancer my ACA provider continues to deny (they approved a year ago)& I’m Stage IV. CT can’t see what were monitoring but they approve CT (I need PET to
Monitor omentum & peritoneal Mets). Lots ofBS from ins RN